Asensus Surgical Stock Gains On FDA Approval For Articulating Instruments For Its Surgical System


Asensus Surgical Inc ASXC has received FDA 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System technology platform. 

  • Articulating instruments offer better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom. 
  • These instruments have previously received CE Mark for use in the European Union.
  • Asensus' Senhance Surgical System is a digital laparoscopic platform that leverages augmented intelligence. 
  • Articulating instruments are the latest addition to the Senhance Surgical System, further enhancing surgical performance with robotic precision.
  • Price Action: ASXC shares are up 8.56% at $2.35 during the market session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareSmall CapFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!